# What Is Tirzepatide? The Dual GIP/GLP-1 Peptide Explained > What is tirzepatide? It is a 39-amino-acid dual GIP and GLP-1 receptor agonist — the first approved twincretin — FDA-approved for type 2 diabetes and obesity. Plain-English explanation with full citations. The first approved medicine to activate two incretin receptors simultaneously — what that means, how it works, and what the science actually shows. ## The short version What is tirzepatide? It is a once-weekly injectable prescription medicine that activates two hormonal pathways at the same time: the GIP pathway and the GLP-1 pathway. Both pathways are activated naturally after eating and help control blood sugar. Most drugs in this family only activate the GLP-1 pathway. Tirzepatide added the second one. The FDA first approved it in May 2022 for type 2 diabetes, then again in November 2023 for chronic weight management, and later for obstructive sleep apnea (a sleep disorder where breathing repeatedly stops). In clinical trials, it produced larger reductions in blood sugar and body weight than any other approved medicine in its class. This page explains what tirzepatide is, how it works at the molecular level, and what [Tirzepatide research](/research) has established about it. ## What is tirzepatide — the molecule Tirzepatide is a synthetic 39-amino-acid peptide — a short protein chain — based on the native GIP (glucose-dependent insulinotropic polypeptide) hormone sequence. Scientists at Eli Lilly modified that backbone by attaching a C20 fatty-diacid chain (eicosanedioic acid) through a glutamic-acid linker. That fatty-acid arm binds tightly to albumin (the most abundant protein in blood), which slows the rate at which the kidneys and liver remove the drug from circulation. The result is an elimination half-life of approximately five days, enabling the once-weekly dosing schedule used in clinical trials and approved on the label [1, 16]. The chemical identifiers: molecular formula C225H348N48O68; molecular weight 4,813.53 Da; CAS number 2023788-19-2; ATC code A10BX16. These are the pharmacopoeial identifiers used to verify that a substance is genuine tirzepatide. The compound is also known by the research name LY3298176, the code Eli Lilly used in preclinical and early clinical development before the INN (international nonproprietary name) tirzepatide was assigned. In the literature before 2020, references to LY3298176 are references to the same molecule [1, 2]. This is a tirzepatide peptide — a peptide drug, not a small molecule. Peptide drugs are derived from or modeled on naturally occurring peptide hormones and are the basis of the entire incretin drug class. ## How does tirzepatide work Tirzepatide activates two gut hormone receptors simultaneously — the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R). Both are G-protein-coupled receptors expressed in the pancreatic beta cells that secrete insulin, in the gut, and in the brain. Activating either receptor in the presence of elevated blood glucose triggers insulin release; activating both together amplifies the insulin secretory response and produces additional metabolic effects. At the GLP-1 receptor: tirzepatide acts as a biased agonist, preferentially activating the cAMP (cyclic adenosine monophosphate — a second messenger that transmits the hormonal signal inside the cell) pathway over the beta-arrestin pathway (which regulates receptor internalization and desensitization). This bias appears to enhance and prolong insulin secretion by keeping the receptor active at the cell surface longer [2]. GLP-1 receptor activation also suppresses glucagon (the hormone that raises blood glucose), slows gastric emptying, and reduces food intake through central appetite circuits. At the GIP receptor: tirzepatide engages the GIPR more completely than the GLP-1R — the compound was classified as an imbalanced dual agonist in receptor-occupancy and signalling assays [2]. GIP receptor activation enhances glucose-dependent insulin secretion and may have beneficial effects on fat tissue metabolism. The combination of both receptor pathways in a single molecule is what makes tirzepatide a 'twincretin' or 'dual incretin agonist' rather than just a GLP-1 receptor agonist. The discovery paper (Coskun 2018) established the proof of concept: in mice, the dual-receptor engagement produced greater weight reduction than a selective GLP-1 receptor agonist, and the 142-subject phase 1 programme in humans showed reduced fasting glucose and body weight versus placebo [1]. The clinical trials then scaled that finding across tens of thousands of participants. ## What is tirzepatide used for — FDA-approved indications Tirzepatide is approved by the U.S. FDA for three indications, each supported by dedicated phase 3 clinical trials: 1. **Type 2 diabetes mellitus (T2DM)** — approved May 2022. The SURPASS programme, comprising five large phase 3 trials in adults with type 2 diabetes, established tirzepatide as superior to all comparators tested, including a selective GLP-1 receptor agonist, insulin glargine, and multiple other background therapies. The label-approved indication is as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes [7, 16]. 2. **Chronic weight management** — approved November 2023. The SURMOUNT programme in adults with obesity (BMI ≥30 kg/m2, or ≥27 kg/m2 with at least one weight-related condition) without type 2 diabetes established mean weight losses of 15–21% over 72 weeks at the three maintenance doses, versus 3.1% with placebo in SURMOUNT-1 [4, 34]. 3. **Obstructive sleep apnea (OSA)** — approved for moderate-to-severe OSA in adults with obesity. The SURMOUNT-OSA trial demonstrated significant reductions in the apnea-hypopnea index (AHI), the standard measure of breathing interruption severity during sleep [35]. Uses not approved or established: tirzepatide is not approved for type 1 diabetes, is not established as a stand-alone treatment for non-alcoholic fatty liver disease (though SYNERGY-MASH results are promising [37]), and is not approved for cardiovascular risk reduction as a primary indication (the SURPASS-CVOT cardiovascular outcomes trial results support safety in high-risk T2DM populations but the label indication is glycemic control in T2DM, not MACE prevention). Use outside these approved indications is off-label, which is a clinical determination. [Tirzepatide references](/references) contains the full citation list. --- Published trial numbers, plain and cited — not a clinic, not a prescription, not a vendor.